Business Context and Reporting Period
Traws Pharma, Inc. (TRAW), a Delaware corporation, filed this Form 8-K on July 29, 2026. The report addresses a regulatory notification regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance triggering the listing deficiency: the closing bid price for the Company's common stock was below $1.00 per share for at least 30 consecutive business days.
Material Changes
The material change reported is the receipt of a notification from the Nasdaq Listing Qualifications Department stating the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement). This notification has no immediate effect on the listing, which remains fully effective.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days from July 29, 2026, until January 25, 2027, to regain compliance.
- Regaining Compliance: Compliance is achieved if the closing bid price is at or above $1.00 per share for a minimum of 10 consecutive business days (potentially extendable to 20 days).
- Second Grace Period: If compliance is not met by January 25, 2027, Nasdaq may grant a second 180-day period if the Company meets other listing standards and notifies Nasdaq of its intent to cure.
- Risks: There is no assurance the Company will regain compliance, secure a second period, or maintain other listing requirements. Failure to comply could result in delisting.
- Management Action: The Company intends to actively monitor the stock price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of TRAW stock relative to the $1.00 threshold.
- Monitor the number of consecutive business days the stock trades above $1.00 to determine if the 10-day compliance window is met.
- Check for any future announcements regarding a second 180-day grace period or delisting notices after January 25, 2027.
- Review the Company's broader financial health in subsequent filings (10-K/10-Q) as this 8-K does not provide operational or financial performance data.